Clinical Trial

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT07562438
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer
Enrollment 20 participants
Start Date 2026-04-29
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-01